Key clinical point: The FDA has approved iobenguane I 131 injection (Azedra) for intravenous use for the treatment of adults and adolescents aged 12 years and older with rare adrenal tumors (pheochromocytoma or paraganglioma) that are unresectable, have metastasized, and require systemic therapy.
Major finding: The primary endpoint was the number of patients with a 50% or greater reduction of antihypertensive medications lasting at least 6 months; the secondary endpoint was overall tumor response according to traditional imaging criteria. Among 68 patients, the primary endpoint was met by 17, and the secondary endpoint was achieved in 15.
Study details: Approval is based on a single-arm, open-label clinical trial that included 68 patients.
Disclosures: The FDA granted the approval of Azedra to Progenics Pharmaceuticals.
FDA approves iobenguane I 131 injection (Azedra) for IV use for pheochromocytoma or paraganglioma.
This Week's Must Reads
Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.
ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.
SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.
Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027
DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.
Must Reads in Genitourinary Cancer
Treating prostate with radiotherapy boosts survival in advanced prostate cancer, Parker C et al. ESMO 2018, Abstract LBA5_PR
Leptin expression may aid in differentiation of renal lesions, Gobe G et al. Pathology. 2018 Aug;50(5):504-10
Hypofractionated radiation offers 'tailored treatment' approach to RCC mets, Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.
Concern over SREs rises with increasing incidence of metastatic RCC, Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002
Radioactive agent approved for adrenal tumors, FDA approves iobenguane I 131 injection (Azedra) for IV use for the treatment of pheochromocytoma or paraganglioma.